Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
60.06 ^USD	-0.40%		-0.92%	-4.36%

Apr. 25	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT
Apr. 22	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	MT

Vaxcyte, Inc.(NasdaqGS:PCVX) added to S&P Biotechnology Select Industry Index

December 21, 2020 at 12:00 am EST

Latest news about Vaxcyte, Inc.

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	Apr. 25	MT
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	Apr. 22	MT
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30	CI
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30	CI
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30	CI
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	Mar. 21	MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating	Mar. 12	MT
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	Mar. 12
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	Mar. 04	CI
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating	Feb. 28	MT
Vaxcyte Q4 Loss Widens	Feb. 27	MT
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	Feb. 02	MT
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	Jan. 31	MT
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	Jan. 31	MT
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	Jan. 31	MT
Vaxcyte Launches Securities Offering; Shares Fall After Hours	Jan. 30	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jan. 29	MT
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate	Jan. 29	MT
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate	Jan. 29	MT
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	Jan. 29	CI
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing	Jan. 25	MT
Vaxcyte Insider Sold Shares Worth $485,879, According to a Recent SEC Filing	Jan. 19	MT

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

60.06 USD

Average target price

103.3 USD

Spread / Average Target

+71.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXCYTE, INC.	-4.36%	6.53B
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs

Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Vaxcyte, Inc.(NasdaqGS:PCVX) added to S&P Biotechnology Select Industry Index

Latest news about Vaxcyte, Inc.

Chart Vaxcyte, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs